The Daily Brief

October 24, 2026

Federal cannabis rescheduling remains in legal limbo as the Trump administration faces ongoing litigation over the April 2026 decision to move state-regulated medical cannabis from Schedule I to Schedule III. The Department of Justice initiated the reclassification process in 2024 following a December 2025 executive order, but a federal judge stayed the rescheduling case in early October 2026, pushing resolution into at least 2027. The delay creates persistent uncertainty for a market that's already fragmented: 41 states and D.C. now operate medical cannabis programs, and 24 states plus D.C. permit adult recreational use, all while federal law technically maintains prohibition—a contradiction that has defined U.S. cannabis policy for over 50 years.

The financial reality of this limbo is stark. Money State-licensed medical operators operate under an effective tax rate exceeding 70 percent of gross profit because the Internal Revenue Service applies IRC §280E (which bars business expense deductions for Schedule I substances) regardless of state compliance and local regulatory frameworks. Moving cannabis to Schedule III would eliminate that penalty, but wouldn't resolve the banking access problem—federally chartered banks still face prosecution risk under 21 U.S.C. §841 if they service cannabis businesses, even in states where the drug is legal. The SAFER Banking Act, which would protect institutions serving state-legal operators, passed the House in 2023 but stalled in the Senate and hasn't been reintroduced.

Texas illustrates the political contradiction at the heart of the rescheduling debate. Texas hemp legalization in 2019 created a practical problem for law enforcement: distinguishing newly legal hemp from its still-prohibited cannabis cousin became so difficult that marijuana arrests dropped by more than half in the six months following the hemp law's implementation. Yet the state government remains cautious on full legalization. Texas House Speaker Dennis Bonnen, acknowledging that legalization "could be a help" to the state's budget shortfall, nonetheless said he would vote against it, arguing that offsetting costs would limit the actual revenue benefit. Meanwhile, the Texas Republican Party's 2018 platform explicitly endorsed marijuana decriminalization and federal rescheduling—positions that reflect the gap between party apparatus and legislative leadership on the issue.

Context A statewide 70 percent support for legalization emerged in Texas's March 2026 Democratic primary, yet the same political environment produces hesitation from Republican leadership citing budget concerns. The disconnect reveals a pattern: public and party platforms have shifted toward normalization, but elected officials cite operational costs and broader fiscal pressures as reasons for inaction. That dynamic extends nationally—the fact that over 155 million Americans now live in states where cannabis is legal, with zero recorded overdose deaths in human history, contrasts sharply with an enforcement and policy framework built around Schedule I placement.

The litigation ahead will determine whether the April 2026 reclassification survives judicial challenge, but even Schedule III status leaves fundamental problems unresolved. Medical dispensaries will still face the 280E tax burden without congressional action on the SAFER Banking Act. Multi-state operators will navigate a patchwork of 41 different medical frameworks plus 24 recreational regimes, each with distinct licensing, testing, and tax structures. Industry observers report that ongoing uncertainty is already complicating supply chain logistics and business scaling decisions. The outcome of the federal lawsuit could clarify the timeline for tax reform and banking access—but only if rescheduling itself is finally allowed to proceed.

October 24, 2026

The global cannabis market is on track to nearly double in size by 2030, with valuations climbing from $45.6 billion in 2025 to $79.3 billion by decade's end—a compound annual growth rate of 11.7 percent. The industry's fragmented competitive landscape, dominated by multi-state operators like Curaleaf, Trulieve, Green Thumb Industries, Verano, Cresco Labs, and Tilray, is consolidating around winners who can scale profitably. Money In the most recent earnings season, Curaleaf led in net revenue at $338.9 million for Q1, while Trulieve posted $298 million and Green Thumb reported $275.8 million—with Green Thumb notably becoming the only major retailer to post a profit in the quarter. Across the board, net losses are shrinking, with Trulieve cutting losses by 32 percent sequentially and Curaleaf's adjusted EBITDA climbing marginally despite seasonal pressure. The message from financial markets is clear: the largest operators are moving toward sustainable profitability even as competition intensifies.

Regulatory tailwinds are accelerating market expansion at both state and federal levels. Virginia's Democratic-controlled legislature passed bills to legalize adult-use cannabis sales nearly five years after decriminalizing possession, potentially allowing the state's five medical cannabis operators to transition to recreational sales by year-end 2026 or early 2027 under a one-time licensing fee. In New York, lawmakers filed companion bills allowing liquor stores to sell low-THC cannabis beverages through a structured permit system, explicitly designed to expand legal access and reduce illicit market activity. Meanwhile, New York cannabis industry associations are pushing the state to absorb the cost of seed-to-sale tracking systems rather than shifting those expenses to operators already competing with an unregulated illicit market that pays nothing. Context As the legal framework expands and enforcement tightens, why do licensed operators still face disadvantages against illegal competitors operating without licensing fees, compliance staff, or tax obligations?

Money Financing infrastructure is maturing alongside the industry. AFC Gamma, a commercial mortgage REIT, expanded its loan portfolio to 15 states in 2025, deploying $10-100 million facilities to state-licensed operators and capitalizing on reduced banking barriers following federal rescheduling discussions. Curaleaf recently closed a $500 million debt offering at 11.5 percent interest, signaling continued access to capital despite analyst headwinds—Jefferies trimmed revenue expectations for Curaleaf, Trulieve, Cronos, and Canopy Growth, though the firm maintained its ratings intact. ETFs like the AdvisorShares Pure US Cannabis ETF (YOLO) are tracking the sector with top holdings in Curaleaf and Green Thumb, offering retail investors diversified exposure to a $57 billion domestic market.

The competitive pressure is real. Verano's Q1 revenues dropped 7 percent sequentially and 3 percent annually to $221 million, a decline the company attributed directly to intensified competition in New Jersey. Yet even as pricing pressure mounts, the industry remains remarkably fragmented—no single operator controls more than a small percentage of the market, leaving substantial consolidation runway for acquisitive leaders. Trulieve's 2021 acquisition of Harvest Health created a combined entity with 149 dispensaries across 11 states and an annual revenue run rate exceeding $1.2 billion, establishing a playbook for scale that competitors are now following. The data suggests winners will be companies that can expand state-by-state within federal banking and licensing constraints, manage costs amid competition, and position for the moment when federal rescheduling removes the final structural disadvantages that currently plague the sector.

October 24, 2026

Texas hemp retailers are operating in a legal whipsaw created by conflicting court rulings and aggressive state enforcement that has fundamentally reshaped the market since May 2026. The Texas Department of State Health Services (DSHS) is now actively enforcing two overlapping sets of restrictions: a July 31 ban on manufactured delta-8, delta-10, THCP, and other synthetic THC isomers classified as Schedule I controlled substances, and a "Total THC Rule" that counts naturally occurring THCA as 88 percent of Delta-9 THC when heated—effectively removing most smokable hemp flower from legal sale. The restrictions followed a Texas Supreme Court ruling in May that allowed DSHS to revive dormant 2021 definitions, ending a five-year injunction that had kept these products legal while litigation moved forward.

Money The financial consequences are immediate and severe. DSHS raised retailer registration fees from $150 to $5,000 annually and manufacturer fees from $250 to $10,000, while enforcement letters have gone out to retailers carrying products that previously passed state testing. The timing has created a contradiction within the industry itself: the Texas Hemp Business Council, the lead plaintiff fighting the restrictions in court, is largely funded by Hometown Hero, an Austin-based retailer and manufacturer founded by CEO Lukas Gilkey that does not sell smokable flower—effectively positioning a major industry player to profit from competitors' inventory becoming illegal. A Travis County judge temporarily blocked the smokable hemp restrictions in May, but the Fifteenth Court of Appeals reversed that order in June, putting enforcement back in play while litigation continues through the state court system.

The new rules target products that retailers began selling after Texas legalized hemp in 2019 under House Bill 1325, which only explicitly banned products with more than 0.3 percent Delta-9 THC by dry weight. DSHS interpreted that statute as implicitly prohibiting manufactured cannabinoid variants like delta-8 (which can be chemically derived from hemp-derived CBD) while grandfathering in naturally occurring trace amounts—a distinction the state has been deliberately vague about. Hemp businesses argue DSHS has exceeded its statutory authority by adopting restrictions that the Texas Legislature never explicitly enacted, a position that will determine whether products currently on retail shelves remain legal or face confiscation.

Context The Texas Supreme Court's reasoning in Sky Marketing Corp. v. DSHS left the legal door open for DSHS to eventually schedule HHC, THCV, THCJD, and other cannabinoids—a broad authority that retailers say transforms the marketplace through administrative rulemaking rather than legislative action. The court didn't rule on whether these restrictions are wise policy, only that the agency had the authority to make them. What remains unresolved is whether DSHS acted within the actual language of Texas law or whether it created new prohibitions administrators were never empowered to make—a question that will likely reach the appellate courts again before 2026 closes.

The hemp market in Texas has become a test case for how states manage the gap between federal hemp legalization and state-level resistance to intoxicating cannabis products. As of October 2026, retailers remain in legal limbo, with enforcement accelerating, court rulings continuing to reverse each other, and the industry's own leadership divided on strategy. DSHS has signaled it's moving forward with enforcement despite ongoing litigation, leaving businesses to navigate inventory decisions, supplier testing protocols, and compliance documentation based on rules that multiple courts have already blocked once. The outcome will likely determine whether other states follow Texas's aggressive reinterpretation approach or whether the courts ultimately force regulators back to the explicit language of the hemp statute.

October 24, 2026

Recent clinical research is demonstrating that cannabis compounds may play a meaningful role in addressing several significant health conditions, from managing acute pain to improving quality of life in dementia patients. Notable A clinical trial highlighted by NORML found that a single dose of cannabis extract significantly reduced the need for opioid medication in acute pain patients—a result that gains additional significance given that prescription opioids kill over 16,000 Americans annually. The Medical University of South Carolina released findings this summer showing that a CBD-THC oil combination helped ease end-of-life agitation in dementia patients, while research from Kentucky documented that the same CBD-THC combination improved quality of life in late-stage dementia patients, suggesting consistent therapeutic benefit across different research institutions.

The scope of potential applications continues expanding. Research on medical marijuana for insomnia published by Medindia examined what current evidence says about its effectiveness for sleep disorders. Separately, work at Renal and Urology News outlined how clinicians are navigating cannabis and CBD use for pain management in patients with rheumatic conditions. A Nature study examining the acute effects of high-THC cannabis inhalation found it increased inflammatory markers, though notably it did not impact insulin sensitivity—adding important nuance to debates about cannabis's metabolic effects. The research diversity here matters: major academic institutions and peer-reviewed journals are now treating cannabis as a legitimate therapeutic investigation space, not a fringe concern.

Context The safety contrast between cannabis and legal alternatives deserves hard numbers. Alcohol kills approximately 95,000 Americans per year. Prescription opioids kill 16,000+. Cannabis has zero recorded overdose deaths in human history. Yet cannabis remains federally Schedule I while both alcohol and opioids remain legal and widely prescribed. As institutions from MUSC to the University of Kentucky publish peer-reviewed evidence of therapeutic applications, the gap between science and law grows wider. The clinical evidence isn't waiting for federal policy to catch up—and patients are watching to see which one changes first.